Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG PENFILL.
HUMALOG MIX 75/25 vs NOVOLOG PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin lispro (25%) and intermediate-acting insulin lispro protamine suspension (75%). Insulin lispro lowers blood glucose by binding to insulin receptors, facilitating cellular glucose uptake, inhibiting hepatic gluconeogenesis, and promoting glycogenesis and lipogenesis.
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Subcutaneous injection: 75% insulin lispro protamine suspension and 25% insulin lispro solution. Dose individualized based on glycemic goals and prior insulin regimen. Typical total daily dose: 0.5-1 unit/kg/day divided into two doses (pre-breakfast and pre-dinner).
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
None Documented
None Documented
Insulin lispro: 0.5-1 hour; protamine-bound fraction prolongs absorption, resulting in a biphasic profile with an effective half-life of 2-4 hours for the 75% NPL component.
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
Renal: 60-80% as unchanged drug following subcutaneous absorption; the remaining fraction undergoes hepatic metabolism and biliary/fecal excretion.
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Category C
Category C
Insulin Analog
Insulin Analog